Biologicals for small tumors and lymphoma

Cao Pharmaceuticals Inc. focuses on developing innovative therapeutic solutions, particularly in the field of drug delivery systems. The company employs advanced technologies to enhance the efficacy and safety of its pharmaceutical products. Their proprietary platforms are designed to optimize the bioavailability of drugs, ensuring that they are delivered effectively to target sites within the body. This approach not only improves patient outcomes but also aims to reduce side effects associated with traditional drug formulations.

In addition to drug delivery, Cao Pharmaceuticals is committed to leveraging cutting-edge research in formulation science. The company explores various methodologies to create stable and effective pharmaceutical formulations, which may include novel excipients and advanced manufacturing techniques. By integrating these technologies, Cao Pharmaceuticals seeks to address unmet medical needs and provide innovative solutions that can significantly impact patient care and treatment efficacy.

United States

Cao Pharmaceuticals is an early clinical stage oncology drug development company with a rich and deep history. We are committed to develop highly effective drugs with low and manageable toxicity for various cancers. And within much shorter timeframes compared to traditional chemotherapy development. Cao Pharmaceuticals is currently conducting a Phase I trial with their lead drug. Phase II trials are scheduled for Q3 2017.

Cao Pharmaceuticals Inc.

Company Details